SCHEMBL27132541

SCHEMBL27132541

CCc1ccc2cnn(C)c2c1NS(=O)(=O)c1cn(-c2ccnc(C(F)(F)F)c2)nc1C

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 2/20 0.36
▸ GRIN1 Q05586 2/20 0.36
▸ GRIN2B Q13224 2/20 0.36
▸ PIK3C3 Q8NEB9 3/20 0.32
▸ ELANE P08246 2/20 0.32
▸ NMT1 P30419 1/20 0.31
▸ SLC40A1 Q9NP59 1/20 0.31
▸ PTGS2 P35354 2/20 0.31
▸ TRPC3 Q13507 1/20 0.31
▸ S1PR1 P21453 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ PTGS1 P23219 1/20 0.30
▸ AR P10275 1/20 0.30
▸ OXTR P30559 1/20 0.30
▸ AVPR1A P37288 1/20 0.30
▸ EDNRB P24530 1/20 0.30
▸ EDNRA P25101 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30847925 1.00 RXRA (0.36) RXRAGRIN1GRIN2BPIK3C3ELANE
SCHEMBL27132346 0.86 RXRA (0.38) RXRAGRIN1GRIN2BELANESLC40A1
SCHEMBL30848041 0.86 RXRA (0.38) RXRAGRIN1GRIN2BELANESLC40A1
SCHEMBL27132536 0.86 RXRA (0.44) RXRAGRIN1GRIN2BSLC40A1AR
SCHEMBL30847869 0.86 RXRA (0.44) RXRAGRIN1GRIN2BSLC40A1AR
SCHEMBL30847962 0.85 GAA (0.32) RXRAGRIN1GRIN2BELANESLC40A1
SCHEMBL27132542 0.85 GAA (0.32) RXRAGRIN1GRIN2BELANESLC40A1
SCHEMBL30847942 0.84 SLC40A1 (0.32) RXRAGRIN1GRIN2BSLC40A1AR
SCHEMBL27132539 0.84 SLC40A1 (0.32) RXRAGRIN1GRIN2BSLC40A1AR
SCHEMBL30847769 0.81 RXRA (0.35) RXRAGRIN1GRIN2BSLC40A1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150321-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. 2024-05-09 — — US disclosed
WO-2024044730-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 — — WO disclosed
WO-2024044730-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-02-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150321-A1 PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL3 RXRA 3175/4885GRIN1 2434/4885GRIN2B 4091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback